These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18574975)

  • 1. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM
    Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract]   [Full Text] [Related]  

  • 2. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 4. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 7. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 8. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 9. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 11. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R; Nitschmann S
    Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract]   [Full Text] [Related]  

  • 14. A third amlodipine/ARB combination (Twynsta) for hypertension.
    Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
    [No Abstract]   [Full Text] [Related]  

  • 15. Early and effective treatment of hypertension: ONTARGET provides some answers.
    Cardiovasc J Afr; 2009; 20(5):323. PubMed ID: 19907811
    [No Abstract]   [Full Text] [Related]  

  • 16. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].
    Del Vecchio L
    G Ital Nefrol; 2008; 25(6):609. PubMed ID: 19048549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.